Daiwa Securities Group
SPRO icon

Daiwa Securities Group’s Spero Therapeutics SPRO Stock Holding History

Daiwa Securities Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110
Closed – – 1381
2022
Q3 		$0 Hold
110
– – ﹤0.01% 1391
2022
Q2 		$0 Hold
110
– – ﹤0.01% 1420
2022
Q1 		$1K Hold
110
– – ﹤0.01% 1339
2021
Q4 		$2K Hold
110
– – ﹤0.01% 1298
2021
Q3 		$2K Buy
110
+59
+116% +$947 ﹤0.01% 1249
2021
Q2 		$1K Hold
51
– – ﹤0.01% 1213
2021
Q1 		$1K Hold
51
– – ﹤0.01% 1224
2020
Q4 		$1K Buy
+51
New +$795 ﹤0.01% 1203

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Daiwa Securities Group's SPRO Position: Q4 2022 in Review

Daiwa Securities Group sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 110 shares.

Daiwa Securities Group first reported a position in SPRO in Q4 2020 and held it in 8 quarters. The position peaked at $2K in Q4 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Daiwa Securities Group reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 110 Spero Therapeutics shares in Q4 2022.
  • Daiwa Securities Group first reported a position in Spero Therapeutics in Q4 2020 and held it in 8 quarters.
  • Daiwa Securities Group's Spero Therapeutics position peaked at $2K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.